查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1519835

2024-2032 年按治療、癌症類型（非小細胞肺癌、小細胞肺癌）、配銷通路和地區分類的肺癌治療市場報告

Lung Cancer Therapeutics Market Report by Therapy, Cancer Type (Non-Small Cell Lung Cancer, Small Cell Lung Cancer ), Distribution Channel, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 137 Pages | 商品交期: 2-3個工作天內

價格

IMARC Group年，全球肺癌治療市場規模達301.888億美元。由於世界各地吸煙和環境污染加劇了肺癌發病率的迅速上升、個體化治療（包括基於基因圖譜的治療）的進一步發展以及技術的不斷進步，市場正在經歷穩定成長。發現病理。

肺癌治療市場分析：

主要市場促進因素：全球範圍內與肺癌相關的大量盛行率和死亡率正在創造較高的肺癌治療市場需求。

主要市場趨勢：隨著越來越多針對腫瘤細胞特定基因突變的療法的出現，市場將朝著個人化醫療的方向發展。此外，將人工智慧和機器學習納入診斷過程可提高獲得此類治療的機會和精確度，這也是肺癌治療市場的主要趨勢之一。

地理趨勢：市場分析表明，由於強大的醫療保健結構、醫療支出和先進腫瘤治療的早期使用，北美在肺癌治療方面處於領先地位。包括中國和印度在內的亞太地區正在憑藉快速成長的醫療保健意識和改進的醫療保健服務系統來推動市場發展。

競爭格局：根據肺癌治療市場概況，基於成熟的製藥巨頭和新興生物公司的存在，市場競爭非常激烈。此外，各大公司正在透過研發和合作夥伴關係來創新和擴展其產品線。

挑戰與機會：新癌症藥物的高成本成為低收入和中等收入經濟體肺癌治療方法的主要挑戰，造成了可近性差距。然而，隨著肺癌治療市場最近開發具有成本效益的學名藥和生物相似藥的機會，這些挑戰變得更加嚴峻。

肺癌治療市場趨勢：

全球肺癌發生率上升

促進肺癌治療市場成長的另一個因素是肺癌發生率的增加。美國癌症協會對美國肺癌的估計，到2024年，新發癌症人數約為234,580人，其中男性116,310人，女性118,270人。死亡人數將達125,070人，其中男性死亡65,790人，女性死亡59,280人。全球人口的指數級成長以及吸煙、空氣和環境污染以及有害工作場所事件等導致肺癌的有害因素的普遍存在都支持了這一點。因此，這也影響著肺癌治療市場的統計數據。由於肺癌發生率不斷增加，需要採取更積極的措施。因此，用於肺癌治療的方法（包括藥物）的開發和改進正在不斷發展。供應的增加為製藥公司進行測試、開發新產品和擴大品種提供了更多理由。因此，對更有效藥物的需求正在成長。因此，肺癌治療是成長最快的。

個人化醫療的創新

隨著個人化醫療的發展，肺癌治療市場的成長正在顯著成長，個人化醫療根據遺傳特徵對每位患者進行治療。近年來，製藥業開發並生產了精確攻擊此類突變的藥物。事實證明，這些藥物比化療更有效，副作用也更少。肺癌治療市場預測表明，個人化醫療將成為該腫瘤治療的基礎；這意味著治療效率會提高，因為處方會更準確。此外，診斷技術的進步以及對影響肺癌進展的遺傳因素的深入了解推動了對精準醫學的日益重視。因此，製藥業對個人化解決方案的投資不斷擴大，使藥物開發與特定患者的需求保持一致，並大大推動肺癌治療市場的發展。

診斷和治療的不斷進步

技術創新推動市場，特別是在診斷和治療方面。此外，改進的影像和人工智慧輔助診斷工具可以更早、更準確地檢測肺癌。除此之外，這個概念也改變了治療效果和患者復原的遊戲規則。除此之外，肺癌治療市場的最新發展包括引入新的和正在開發的微創手術技術、增強的放射治療方法和先進的藥物傳輸系統，包括基於奈米顆粒的化療製劑。此外，先進技術的準確性和有效性無法想像舒適的治療和可恢復的患者視野。此外，所有這些技術的結合正在創造積極的市場前景。

肺癌治療市場細分：

IMARC Group提供了每個細分市場的主要趨勢分析，以及 2024-2032 年全球、區域和國家層面的預測。我們的報告根據治療、癌症類型和配銷通路對市場進行了分類。

治療分手：

標靶治療

貝伐珠單抗

達拉非尼/曲美替尼

鹽酸厄洛替尼

奧西替尼

其他

免疫療法

杜瓦魯單抗

納武單抗

阿替珠單抗

帕博利珠單抗

放射治療

外樑

內樑

系統性

化療

標靶治療佔據大部分市場佔有率

該報告根據該療法對市場進行了詳細的細分和分析。這包括標靶治療（貝伐珠單抗、達拉非尼/曲美替尼、鹽酸厄洛替尼、奧西替尼等）；免疫療法（durvalumab、nivolumab、atezolizumab 和 pembrolizumab）；放射治療（體外、內照射和全身放射治療）；和化療。根據該報告，標靶治療佔最大部分。

該療法是最大的，因為與傳統化療相比，它更有效且副作用更少。它包括能夠準確識別和殺死癌細胞的藥物或其他材料。這種治療可能針對區分癌細胞與其他細胞的分子和遺傳特徵。此外，目前對肺癌遺傳的了解程度允許識別許多特定的分子靶點，以及相應地可以阻止這些標靶活化的藥物。根據肺癌治療市場預測，分子生物學和遺傳學的發展將不斷增加可用於對抗所述疾病的標靶和藥物的數量。因此，有理由認為，由於新的潛在標靶和藥物的出現，標靶治療領域將繼續發展。

按癌症類型分類：

非小細胞肺癌 (NSCLC)

小細胞肺癌 (SCLC)

非小細胞肺癌（NSCLC）佔據業界最大佔有率

報告還根據癌症類型提供了詳細的市場細分和分析。這包括非小細胞肺癌（NSCLC）和小細胞肺癌（SCLC）。報告顯示，非小細胞肺癌（NSCLC）佔據最大的肺癌治療市場。

非小細胞肺癌由於其高盛行率而在市場上佔據最大佔有率。就個體而言，這些亞型具有共同的病理變異，但它們的進展速度比小細胞肺癌慢。因此，全球非小細胞肺癌的高盛行率對不同亞型的肺癌治療市場產生了巨大的需求，從而激勵製藥公司和研究人員專注於開發能夠有效治療亞型基因和分子差異的療法和免疫療法。此外，NSCLC分子發病機制不斷變化的能力也保證了精準醫療的發展使得NSCLC與市場具有相關性。

按配銷通路分類：

醫院藥房

零售藥局

網路藥局

其他

醫院藥房代表領先的細分市場

該報告根據配銷通路對市場進行了詳細的細分和分析。這包括醫院藥房、零售藥房、線上藥房等。報告稱，醫院藥局是最大的細分市場。

由於肺癌治療方法的複雜性和先進性，醫院藥局是肺癌治療領域最大的通路。醫生需要在受控環境下進行治療，包括化療方案，需要仔細調節以避免副作用。根據肺癌治療市場分析，大多數肺癌治療都是針對住院患者，因為需要化療、標靶治療和免疫治療等複雜治療根據肺癌治療市場分析，大多數肺癌治療都是針對住院患者，因為需要化療、標靶治療和免疫療法用於化療、標靶治療和免疫療法等複雜療法。此外，醫院藥局對於促進肺癌綜合護理至關重要，因為患者可以立即從同一家可以協調腫瘤科、外科和放射科的醫院獲得所有所需的治療。除此之外，中心性的集中確保患者以最小的延遲接受治療，從而提高治療的有效性。此外，對基礎設施和人員專業知識的需求正在增加肺癌治療市場的收入。

按地區分類：

北美洲

美國

加拿大

亞太

中國

日本

印度

韓國

澳洲

印尼

其他

歐洲

德國

法國

英國

義大利

西班牙

俄羅斯

其他

拉丁美洲

巴西

墨西哥

其他

中東和非洲

北美市場領先，佔據最大的肺癌治療市場佔有率

該報告還對所有主要區域市場進行了全面分析，其中包括北美（美國和加拿大）；亞太地區（中國、日本、印度、韓國、澳洲、印尼等）；歐洲（德國、法國、英國、義大利、西班牙、俄羅斯等）；拉丁美洲（巴西、墨西哥等）；以及中東和非洲。報告稱，北美是肺癌治療的最大區域市場。

由於疾病盛行率高、醫療基礎設施先進以及醫療支出最高的因素之一，北美擁有最大的區域肺癌治療市場佔有率。除此之外，美國和歐元區國家在研發方面的高額政府貢獻和私營部門支持也在北美市場的成長中發揮關鍵作用。此外，加速投資開發診斷和治療肺癌的技術和措施正在積極影響肺癌治療市場的收入。正如肺癌治療市場成長趨勢所示，在過去十年中，各種標靶療法和免疫療法已被開發並用於肺癌的治療。此外，整個地區的監管環境也有對癌症藥物快速通道的友善政策。此外，整個地區患者的高水準意識和保險覆蓋範圍確保北美繼續主導全球市場。

本報告回答的關鍵問題：

  • 迄今為止，全球肺癌治療市場表現如何，未來幾年將如何表現？
  • 全球肺癌治療市場的促進因素、限制因素和機會是什麼？
  • 每個促進因素、限制因素和機會對全球肺癌治療市場有何影響？
  • 主要區域市場有哪些？
  • 哪些國家代表了最具吸引力的肺癌治療市場？
  • 基於該療法的市場區隔是什麼？
  • 肺癌治療市面上哪種療法最具吸引力？
  • 根據癌症類型分類的市場是怎麼樣的？
  • 肺癌治療市場中哪種癌症類型最具吸引力？
  • 基於配銷通路的市場區隔是什麼？
  • 肺癌治療市場中最具吸引力的配銷通路是什麼？
  • 市場競爭結構如何？
  • 誰是全球肺癌治療市場的主要參與者/公司？

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 資料來源
    • 主要資源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球肺癌治療市場

  • 市場概況
  • 市場業績
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：透過療法

  • 標靶治療
    • 市場走向
    • 關鍵環節
      • 貝伐珠單抗
      • 達拉非尼/曲美替尼
      • 鹽酸厄洛替尼
      • 奧西替尼
      • 其他
    • 市場預測
  • 免疫療法
    • 市場走向
    • 關鍵環節
      • 杜瓦魯單抗
      • 納武單抗
      • 阿替珠單抗
      • 帕博利珠單抗
    • 市場預測
  • 放射治療
    • 市場走向
    • 關鍵環節
      • 外樑
      • 內樑
      • 系統性
    • 市場預測
  • 化療
    • 市場走向
    • 市場預測

第 7 章：市場區隔：按癌症類型

  • 非小細胞肺癌（NSCLC）
    • 市場走向
    • 市場預測
  • 小細胞肺癌 (SCLC)
    • 市場走向
    • 市場預測

第 8 章：市場區隔：按配銷通路

  • 醫院藥房
    • 市場走向
    • 市場預測
  • 零售藥局
    • 市場走向
    • 市場預測
  • 網路藥局
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 9 章：市場區隔：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場走向
    • 市場細分：按國家/地區
    • 市場預測

第 10 章：促進因素、限制與機會

  • 概述
  • 促進要素
  • 限制
  • 機會

第 11 章：價值鏈分析

第 12 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 13 章：價格分析

第14章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • AbbVie Inc.
    • Amgen Inc.
    • AstraZeneca Plc
    • Boehringer Ingelheim International GmbH
    • Bristol-Myers Squibb Company
    • Daiichi Sankyo Company Limited
    • Eli Lilly and Company
    • GSK PLC
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Roche Holding AG
    • Takeda Pharmaceutical Company Limited
Product Code: SR112024A8336

The global lung cancer therapeutics market size reached US$ 30,188.8 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 70,084.5 Million by 2032, exhibiting a growth rate (CAGR) of 9.52% during 2024-2032. The market is experiencing steady growth driven by the rapid increase in the incidence of lung cancer, which is aggravated by smoking and environmental pollution around the world, the further development of individualized treatment, including based on the gene profile, and the continuous advancement of technology for diagnosing the disease, to ensure early detection of the pathology.

Lung Cancer Therapeutics Market Analysis:

Major Market Drivers: The massive prevalence and mortality associated with lung cancer worldwide is creating a high lung cancer therapeutics market demand.

Key Market Trends: The market will develop in the direction of personalized medicine as an increasing number of therapies addressing particular genetic mutations in tumor cells are created. Additionally, the incorporation of AI and machine learning in the diagnostic processes enhancing the chances and precision of accessing such treatments is acting as one of the major lung cancer therapeutics market trends.

Geographical Trends: The market analysis states that North America leads the market regarding lung cancer therapeutics due to the robust healthcare structures, health expenditures, and early use of advanced oncology treatments. Asia Pacific region, including China and India, is driving the market based on rapidly growing healthcare awareness and improved healthcare delivery systems.

Competitive Landscape: According to the lung cancer therapeutics market overview, the market is highly competitive based on the existence of well-established pharmaceutical giants and new emerging biofirms. Additionally, major companies are innovating and expanding their product lines through research and development and partnerships.

Challenges and Opportunities: The high cost of new cancer medicines emerges as the main challenge to the lung cancer therapeutics revelations to the low- and middle-income economies, creating accessibility gaps. However, such challenges amplify as lung cancer therapeutics market recent opportunities for developing cost-effective generics and biosimilars.

Lung Cancer Therapeutics Market Trends:

Rising incidence of lung cancer worldwide

Another factor contributing to the lung cancer therapeutics market growth is the increasing incidence of lung cancer. The American Cancer Society made an estimation of lung cancer in the US by 2024. The number of new cancer occurrences should approximately equal 234,580 individuals, including 116,310 males and 118,270 females. The number of deaths will equal 125,070 deaths, which involves 65,790 male deaths and 59,280 female deaths. This can be supported by the exponentially growing global population and the prevalence of harmful factors causing lung cancer such as smoking, air and environmental pollution, and harmful workplace events. Thus, this is also influencing the lung cancer therapeutics market statistics. Due to the constantly increasing incidence of lung cancer, more active measures are needed. Accordingly, the development and improvement of methods, including drugs, for lung cancer treatment are constantly developing. Increased supply creates more reason for pharmaceutical companies to conduct tests and develop new ones and expand their assortment. Accordingly, demand for more effective drugs is growing. Thus, lung cancer therapeutics is the fastest-growing.

Innovations in personalized medicine

The lung cancer therapeutics market growth is increasing significantly with the development of personalized medicine, which treats each patient based on genetic features. In recent years, the drug industry has developed and produced drugs that precisely attack such mutations. These have proven to be more effective than chemotherapy, causing fewer side effects. The lung cancer therapeutics market forecast suggests that personalized medicine will become the basis of therapy for this oncology; this means an increase in the efficiency of therapy since the prescription will be more accurate. Furthermore, the growing emphasis on precision medicine is fueled by technological progress in diagnostics and an increased understanding of genetic factors influencing lung cancer progression. Consequently, the pharmaceutical industry's investment in personalized solutions continues to expand, aligning drug development with specific patient needs and substantially driving the lung cancer therapeutics market forward.

Continuous advancements in diagnostics and treatment

Technological innovations drive the market, particularly in diagnostics and treatment delivery. In addition, improved imaging and AI-assisted diagnostic tools allow lung cancer detection early and more accurately. Along with this, this notion is a game-changer for treatment efficacy and patient recovery. Apart from this, the lung cancer therapeutics market recent developments include the introduction of new and developing minimally invasive surgery techniques, enhanced radiation treatment approaches, and advanced drug-delivery systems, including nanoparticle-based chemo preparations. In addition, the accuracy and effectiveness of advanced technology cannot imagine a comfortable treatment and recoverable patient view. Furthermore, the combination of all these technologies is creating a positive market outlook.

Lung Cancer Therapeutics Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on therapy, cancer type, and distribution channel.

Breakup by Therapy:

Targeted Therapy

Bevacizumab

Dabrafenib/Trametinib

Erlotinib Hydrochloride

Osimertinib

Others

Immunotherapy

Durvalumab

Nivolumab

Atezolizumab

Pembrolizumab

Radiation Therapy

External Beam

Internal Beam

Systemic

Chemotherapy

Targeted therapy accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the therapy. This includes targeted therapy (bevacizumab, dabrafenib/trametinib, erlotinib hydrochloride, Osimertinib and others); immunotherapy (durvalumab, nivolumab, atezolizumab and pembrolizumab); radiation therapy (external beam, internal beam and systemic); and chemotherapy. According to the report, targeted therapy represented the largest segment.

The therapy segment is the largest as it is more efficient and has fewer side effects compared to traditional chemotherapy. It includes drugs or other materials that can accurately recognize and kill cancer cells. This treatment is probably directed at the molecular and genetic features that differentiate cancer cells from others. In addition, the current level of understanding of genetic aspects of lung cancer allows the identification of many specific molecular targets and, correspondingly, agents that can prevent the activation of these targets. According to the lung cancer therapeutics market forecast, the development of molecular biology and genetics will consistently increase the number of targets and agents that could be used to combat the described disease. Hence, it is reasonable to suppose that the targeted therapy segment will continue developing due to the appearance of new potential targets and agents.

Breakup by Cancer Type:

Non-Small Cell Lung Cancer (NSCLC)

Small Cell Lung Cancer (SCLC)

Non-Small Cell Lung Cancer (NSCLC) holds the largest share of the industry

A detailed breakup and analysis of the market based on the cancer type have also been provided in the report. This includes non-small cell lung cancer (NSCLC), and small cell lung cancer (SCLC). According to the report, non-small cell lung cancer (NSCLC) accounted for the largest lung cancer therapeutics market share.

The non-small cell lung cancer segment holds the largest share in the market due to its high prevalence. Individually, the subtypes share pathological variations, but they progress more slowly than small-cell lung cancer. As such, the high global prevalence of NSCLC creates a sizable lung cancer therapeutics market demand for the different subtypes, thereby incentivizing pharmaceutical companies and researchers to focus on developing therapies and immunotherapies that can treat the subtype gene and molecular distinctions effectively. In addition, the changing molecular pathogenesis capacity for NSCLC also ensures that the development of precision medicine causes NSCLC to have a correlation with the market.

Breakup by Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Other

Hospital pharmacies represents the leading market segment

The report has provided a detailed breakup and analysis of the market based on the distribution channel. This includes hospital pharmacies, retail pharmacies, online pharmacies, and others. According to the report, hospital pharmacies represented the largest segment.

Hospital pharmacies are the largest channel of distribution in the lung cancer therapeutics segment due to the complicated and advanced nature of the therapies for the disease. Doctors require a controlled environment to administer treatments, including chemotherapy solutions, which need to be carefully regulated to avoid side effects. According to the lung cancer therapeutics market analysis, most lung cancer therapies are for inpatients given the need for complex therapies such as chemotherapy, targeted therapy, and immunotherapies According to the lung cancer therapeutics market analysis, most lung cancer therapies are for inpatients given the need for complex therapies such as chemotherapy, targeted therapy, and immunotherapies. Additionally, hospital pharmacies are critical in facilitating integrated lung cancer care as the patient can access all the required treatments immediately and from the same hospital that can coordinate oncology, surgery, and radiology departments. Apart from this, the centralization of centrality ensures the patient undergoes therapy with minimal delays which improves the effectiveness of the therapeutics. Furthermore, the demand for infrastructure and personnel expertise is increasing the lung cancer therapeutics market revenue.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America leads the market, accounting for the largest lung cancer therapeutics market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for lung cancer therapeutics.

North America has the largest regional lung cancer therapeutics market share due to high disease prevalence, advanced healthcare infrastructure, and one of the highest healthcare spender factors. Along with this, high government contribution and private sector support in the US and Eurozone countries, spent on research and development, also play a key role in the growth of the North American market. Furthermore, the accelerating investments to develop technologies and initiatives to diagnose and treat lung cancer are influencing lung cancer therapeutics market revenue positively. As the lung cancer therapeutics market growth trend shows, in the past decade, various targeted therapies and immunotherapies have been developed and used in the treatment of lung cancer. Furthermore, the regulatory environment across the region also has a friendly policy of fast-track cancer drugs. Moreover, the high levels of patient awareness across the region, and insurance coverage ensures North America continues to dictate the global market.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the lung cancer therapeutics industry include:

AbbVie Inc.

Amgen Inc.

AstraZeneca Plc

Boehringer Ingelheim International GmbH

Bristol-Myers Squibb Company

Daiichi Sankyo Company Limited

Eli Lilly and Company

GSK PLC

Merck & Co. Inc.

Novartis AG

Pfizer Inc.

Roche Holding AG

Takeda Pharmaceutical Company Limited

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

The major lung cancer therapeutics market companies swiftly develop their product portfolios. As R&D remains critically important in their aim to expand, these companies, Roche, Pfizer, AstraZeneca, and other influential giants, are recognized as the most innovative pharmaceutical firms globally. In particular, they are developing targeted therapy and immunotherapy, which showed encouraging outcomes in addressing numerous lung cancer subtypes. Therefore, this is acting as one of the major market trends. In addition, the companies invest in advanced clinical trials to develop new indication opportunities, significantly expanding the imaginable market for their products. Furthermore, the M&A activity is also very high in the industry where several companies attempt to purchase all competitors and utilize all the latest technology available on the market. Thus, the need to stay competitive in the market for therapeutic results and improved patient outcomes.

Lung Cancer Therapeutics Market News:

March 26, 2024: AbbVie Inc. entered into a definitive agreement to acquire clinical-stage biopharmaceutical company Landos Biopharma for $212.5 million. The optimal acquisition strengthens AbbVie's pipeline in its target therapeutic area of inflammatory and autoimmune diseases.

March 19, 2024: AstraZeneca Plc acquired oncology biotech Fusion Pharmaceuticals for $2.4bn, acquiring expertise in a developing field of a less toxic and more targeted form of radiotherapy to catch up with the Swiss Novartis.

Key Questions Answered in This Report:

  • How has the global lung cancer therapeutics market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global lung cancer therapeutics market?
  • What is the impact of each driver, restraint, and opportunity on the global lung cancer therapeutics market?
  • What are the key regional markets?
  • Which countries represent the most attractive lung cancer therapeutics market?
  • What is the breakup of the market based on the therapy?
  • Which is the most attractive therapy in the lung cancer therapeutics market?
  • What is the breakup of the market based on the cancer type?
  • Which is the most attractive cancer type in the lung cancer therapeutics market?
  • What is the breakup of the market based on the distribution channel?
  • Which is the most attractive distribution channel in the lung cancer therapeutics market?
  • What is the competitive structure of the market?
  • Who are the key players/companies in the global lung cancer therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Lung Cancer Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Therapy

  • 6.1 Targeted Therapy
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Bevacizumab
      • 6.1.2.2 Dabrafenib/Trametinib
      • 6.1.2.3 Erlotinib Hydrochloride
      • 6.1.2.4 Osimertinib
      • 6.1.2.4 Others
    • 6.1.2 Market Forecast
  • 6.2 Immunotherapy
    • 6.2.1 Market Trends
    • 6.2.2 Key Segments
      • 6.2.2.1 Durvalumab
      • 6.2.2.2 Nivolumab
      • 6.2.2.3 Atezolizumab
      • 6.2.2.4 Pembrolizumab
    • 6.2.2 Market Forecast
  • 6.3 Radiation Therapy
    • 6.3.1 Market Trends
    • 6.3.2 Key Segment
      • 6.3.2.1 External Beam
      • 6.3.2.2 Internal Beam
      • 6.3.2.3 Systemic
    • 6.3.2 Market Forecast
  • 6.4 Chemotherapy
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Cancer Type

  • 7.1 Non-small Cell Lung Cancer (NSCLC)
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Small Cell Lung Cancer (SCLC)
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospital Pharmacies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Retail Pharmacies
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Pharmacies
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 AbbVie Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2 Amgen Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 AstraZeneca Plc
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 Boehringer Ingelheim International GmbH
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Bristol-Myers Squibb Company
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 Daiichi Sankyo Company Limited
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
    • 14.3.7 Eli Lilly and Company
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 GSK PLC
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
    • 14.3.9 Merck & Co. Inc.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
    • 14.3.10 Novartis AG
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
    • 14.3.11 Pfizer Inc.
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
    • 14.3.12 Roche Holding AG
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
    • 14.3.13 Takeda Pharmaceutical Company Limited
      • 14.3.13.1 Company Overview
      • 14.3.13.2 Product Portfolio

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

List of Figures

  • Figure 1: Global: Lung Cancer Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2018-2023
  • Figure 3: Global: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 4: Global: Lung Cancer Therapeutics Market: Breakup by Therapy (in %), 2023
  • Figure 5: Global: Lung Cancer Therapeutics Market: Breakup by Cancer Type (in %), 2023
  • Figure 6: Global: Lung Cancer Therapeutics Market: Breakup by Distribution Channel (in %), 2023
  • Figure 7: Global: Lung Cancer Therapeutics Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Lung Cancer Therapeutics (Targeted Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Lung Cancer Therapeutics (Targeted Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Lung Cancer Therapeutics (Immunotherapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Lung Cancer Therapeutics (Immunotherapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Lung Cancer Therapeutics (Radiation Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Lung Cancer Therapeutics (Radiation Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Lung Cancer Therapeutics (Chemotherapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Lung Cancer Therapeutics (Chemotherapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Lung Cancer Therapeutics (Non-small Cell Lung Cancer (NSCLC)) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Lung Cancer Therapeutics (Non-small Cell Lung Cancer (NSCLC)) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Lung Cancer Therapeutics (Small Cell Lung Cancer (SCLC)) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Lung Cancer Therapeutics (Small Cell Lung Cancer (SCLC)) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Lung Cancer Therapeutics (Hospital Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Lung Cancer Therapeutics (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Lung Cancer Therapeutics (Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Lung Cancer Therapeutics (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Lung Cancer Therapeutics (Online Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Lung Cancer Therapeutics (Online Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Lung Cancer Therapeutics (Other Distribution Channels) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Lung Cancer Therapeutics (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: North America: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: North America: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: United States: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: United States: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Canada: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Canada: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Asia-Pacific: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Asia-Pacific: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: China: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: China: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Japan: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Japan: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: India: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: India: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: South Korea: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: South Korea: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Australia: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Australia: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Indonesia: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Indonesia: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Others: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Others: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Europe: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Europe: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Germany: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Germany: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: France: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: France: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: United Kingdom: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: United Kingdom: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Italy: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Italy: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Spain: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Spain: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Russia: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Russia: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Others: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Others: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Latin America: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Latin America: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Brazil: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Brazil: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Mexico: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Mexico: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Others: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Others: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Middle East and Africa: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Middle East and Africa: Lung Cancer Therapeutics Market: Breakup by Country (in %), 2023
  • Figure 76: Middle East and Africa: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Global: Lung Cancer Therapeutics Industry: Drivers, Restraints, and Opportunities
  • Figure 78: Global: Lung Cancer Therapeutics Industry: Value Chain Analysis
  • Figure 79: Global: Lung Cancer Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Lung Cancer Therapeutics Market: Key Industry Highlights, 2023 & 2032
  • Table 2: Global: Lung Cancer Therapeutics Market Forecast: Breakup by Therapy (in Million US$), 2024-2032
  • Table 3: Global: Lung Cancer Therapeutics Market Forecast: Breakup by Cancer Type (in Million US$), 2024-2032
  • Table 4: Global: Lung Cancer Therapeutics Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 5: Global: Lung Cancer Therapeutics Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Lung Cancer Therapeutics Market: Competitive Structure
  • Table 7: Global: Lung Cancer Therapeutics Market: Key Players